1. Field of the Invention
The present invention relates to an apparatus for evaluating blood platelet functionality. More specifically, the invention relates to an improved multicell cartridge for use in evaluating blood platelet functionality and method for using the same.
2. Description of the Prior Art
It has been observed that blood platelets play a significant role in the clotting or coagulation of whole blood. When platelets are activated, they shorten the clotting time of the blood. This shortening is related to the initial status of the platelets and platelet disfunction is considered a leading cause of post-surgical bleeding following cardiopulmonary bypass surgery.
Blood platelet functionality is conventionally determined by mixing blood and a clot promoting reagent such as kaolin in a buffer solution. This is done in a series of test cells incorporated in a test cartridge. After adding the clotting reagent, the blood/kaolin solution in each cell is agitated to activate the platelets to promote clotting. The degree of agitation of the blood sample in each cell differs one from the other. As described in U.S. Pat. No. 5,314,826, the clotting time is proportional to the degree of agitation. By comparing clotting times of aliquots of the blood as a function of degree of agitation, the blood platelet functionality can be determined. This process and the apparatus for carrying it out are disclosed in detail in U.S. Pat. Nos. 4,599,219 and 5,314,826. Where necessary for a further understanding of the present invention, the disclosures in these two patents are incorporated by reference herein.
Chemical platelet activators or reagents are well-known in the art. One such activator, 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine, a biologically active phospholipid, is disclosed in Demopoulos, et al., J. Biol. Chem., 1979; 254:9355-8. This platelet activator or reagent, often referred to as a platelet activating factor, enhances the ability of active platelets to effectively participate in the blood clotting reaction and thereby shorten the clotting time of the blood. If the platelets are inactive or not functioning normally, the activator will have a lessened or no effect on the clotting time.
It is the principal object of the present invention to provide an improved platelet functionality test cartridge that facilitates the evaluation of functional platelets in a blood sample.
Another object of the present invention is to provide a test cartridge that, upon receipt of blood sample aliquots therein, provides clotting results that are predictive of platelet activity.
In accordance with the foregoing objects, the present invention is embodied in a cartridge having a plurality of test cells. Each cell is adapted for receiving an aliquot part of a blood sample. A measured amount of platelet activating reagent is applied in the reaction chamber of each cell as a dried fill. The amount of reagent in each cell differs from the amount of reagent in each other cell, at least one of the cells containing no platelet activating reagent. Additionally, amounts of heparin or protamine may be added in each cell either as a liquid or a dried fill. The cells also include a clotting reagent such as kaolin which on use of the cartridge is inserted into the reaction chamber and mixed with the blood and platelet activating reagent. The relative clotting times of the samples in each of the cells are measured and, when compared to a standard and each other, determine the platelet functionality of the blood sample.
The cartridge and method of determining platelet functionality is useful in connection with open heart and cardiopulmonary surgery wherein the blood condition of the patient must be closely monitored.
The present invention is embodied in a test cartridge 10 having a plurality of test cells 11, preferably six such cells, depending from and integral with a cartridge plate 12 having a frond depending skirt or panel 14. The cartridge is adapted to be inserted into a test apparatus such as shown in FIG. 4 and described in detail in U.S. Pat. No. 4,599,219 for the determination of clotting time of an aliquot blood sample inserted into each test cell 11 as described in detail in said patent. For example, as described in column 17, lines 24-31 of U.S. Pat. No. 4,599,219, the upward and downward movement of the slide rods 388 also lifts and lowers the lift wire 372. As shown in
A clotting reagent 29, such as kaolin in a buffered, bacteriostatic solution, is contained in the clotting reagent chamber 25 above the plug 20 and below the seal washer 24. When the cartridge is used, the plunger 21 of each cell is lifted and the plug 20 is pushed upwardly, thereby forcing the clotting reagent into the blood sample contained in the upper cell reaction chamber 26 to initiate clotting.
In accordance with the present invention, a measured amount of a chemical platelet activating factor or reagent 30 is provided in the top or upper reaction chamber 26 as a dried fill. This platelet activating factor composition is dissolved in the blood sample when the blood sample is introduced into the upper reaction chamber 26 and the clotting reagent 29 is added and mixed therein. Additionally, selected amounts of heparin or protamine may be utilized as a dried fill in the upper reaction chamber 26, depending on the chemical procedure to be utilized.
In order to provide a series of differing clotting times, the amount of platelet activating factor in each cell differs from the amount in each other cell. In the first two cells 11A and 11B (as shown in FIG. 1), no platelet activating factor is utilized. In each succeeding cell 11C, 11D, 11E and 11F, increasing amounts of platelet activating factor or reagent are utilized.
The preferred platelet activating factor is the compound 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine, a biologically active phospholipid. Other factors or compounds which may be used are collagen, epinephrine, ristocetin and arachidonic acid. Fills of the preferred platelet activating factor, 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine, are prepared by mixing the factor with a saline (NaCl) solution containing 0.25% bovine serum albumin, and diluting with deionized water to the desired factor concentrations. An amount of each solution of the desired factor concentration is placed in a cell and allowed to evaporate, leaving a solid or dry fill residue of the desired amount of platelet activating factor. Desired amounts of heparin and protamine may also be added and dried as a fill.
The clotting reagent, such as kaolin, is prepared as a 4% w/v suspension in hydroxyethylpiperazine ethanesulfonic acid buffer with 0.5 m calcium chloride, and sodium azide as a bacteriostatic agent. The amount of 0.088 ml of this clotting reagent is loaded into the reagent chamber 25 of each cell 11 of the cartridge 10.
In use, aliquots of 0.35 ml per cell of a blood sample are dispensed into each cell. This results in platelet activating factor (PAF) blood concentrations illustratively shown in the following Table.
After introducing the blood samples in each upper reaction chamber 26, the clotting reagent is inserted into each upper reaction chamber and the clotting time of the blood in each cell is determined. From the clotting time for each cell, the clot ratio is calculated. Clot ratio is the ratio of the clotting times for cells C, D, E and F compared to the average control clotting times for cells A and B. Platelet function is expressed as a percentage of the maximum clot ratio response observed in a normal population. This value of a normal population response is known and can be used to compute the clot ratio percentage which is in turn indicative of the platelet functionality. Any appropriate desired calculation may be made from the relative clotting times in each cell. The platelet functionality can in turn be utilized to determine blood loss during surgery and the need for a blood transfusion. The platelet functionality further assists in managing heparin therapy during cardiac surgery.
As referred to above, the titration curve can be normalized by converting the clotting times to ratios. The clotting time of Cell A, with no platelet activating factor present, is the cell clotting time to which all other cell clotting times are compared. The ratio is calculated by dividing the Cell A clotting time in seconds by each other cell clotting time in seconds. A clot ratio is then calculated as 1 minus the ratio of cell A clotting time to other cell clotting times (1−cellAtime/cellxtime). Data can also be presented in terms of platelet function as a percentage of normal. This is calculated from the clot ratio by multiplying the clot ratio by 100 and then by a factor of 1.97 which has been determined by measuring the maximum platelet activating factor response in 22 normal donors. These donors had no known platelet disfunction and were taking no known medications.
The test cartridge and method described herein are useful for providing a simple and rapid response point-of-care platelet function assay. This assay identifies patients with excessive post-cardiopulmonary bypass blood loss who could benefit from further blood treatment and management.
While a certain illustrative embodiment of the present invention has been shown in the drawings and described above in detail, it should be understood that there is no intention to limit the invention to the specific form disclosed. On the contrary, the intention is to cover all modifications, alternative constructions and compositions, equivalents and uses falling within the spirit and scope of the invention as expressed in the appended claims.
This application is a divisional of U.S. patent application Ser. No. 08/640,275, filed Apr. 30, 1996, now issued as U.S. Pat. No. 5,925,319.
Number | Name | Date | Kind |
---|---|---|---|
3077106 | Fink | Feb 1963 | A |
3307392 | Owen et al. | Mar 1967 | A |
3450501 | Oberhardt | Jun 1969 | A |
3492096 | Hattersley | Jan 1970 | A |
3560162 | Mittleman | Feb 1971 | A |
3560163 | Mittleman | Feb 1971 | A |
3587295 | Simons | Jun 1971 | A |
3635678 | Seitz et al. | Jan 1972 | A |
3650698 | Adler | Mar 1972 | A |
3658480 | Kane et al. | Apr 1972 | A |
3692487 | Sanz | Sep 1972 | A |
3695842 | Mintz | Oct 1972 | A |
3699437 | Ur | Oct 1972 | A |
3704099 | Sanz | Nov 1972 | A |
3719075 | Mandrona et al. | Mar 1973 | A |
3741002 | Simons | Jun 1973 | A |
3814585 | Bailly | Jun 1974 | A |
3836333 | Mintz | Sep 1974 | A |
3911728 | Fixot | Oct 1975 | A |
3918908 | Moyer et al. | Nov 1975 | A |
4131549 | Ferrara | Dec 1978 | A |
4197735 | Munzer et al. | Apr 1980 | A |
4210623 | Breno et al. | Jul 1980 | A |
4329302 | Hanahan et al. | May 1982 | A |
4443408 | Mintz | Apr 1984 | A |
4599219 | Cooper et al. | Jul 1986 | A |
4752449 | Jackson et al. | Jun 1988 | A |
4780418 | Kratzer | Oct 1988 | A |
4782026 | Baugh et al. | Nov 1988 | A |
4788139 | Ryan | Nov 1988 | A |
4795703 | Folkman et al. | Jan 1989 | A |
4871677 | Baugh et al. | Oct 1989 | A |
4876069 | Jochimsen | Oct 1989 | A |
5091304 | La Duca et al. | Feb 1992 | A |
5174961 | Smith | Dec 1992 | A |
5314826 | Baugh | May 1994 | A |
5705198 | Triplett et al. | Jan 1998 | A |
5716796 | Bull et al. | Feb 1998 | A |
5925319 | Baugh et al. | Jul 1999 | A |
5951951 | Lane et al. | Sep 1999 | A |
5972712 | Baugh et al. | Oct 1999 | A |
Number | Date | Country | |
---|---|---|---|
Parent | 08640275 | Apr 1996 | US |
Child | 09330544 | US |